secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001104659-25-097799
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode acquires ABCJ, gets $25M investment from DEFJ, appoints new CEO
-------------------------------------------------------------------------

- Acquired 100% of ABCJ for 83,285 common shares (9.99% of pre-close), convertible preferred, and up to $95M milestone payments.
- DEFJ invests $25M via Series B convertible preferred ($20M cash + $5M promissory note due Jan 1, 2026 at 4% interest).
- Shareholders as of Oct 20, 2025 receive one CVR per share entitling to 50% of future milestone proceeds (7-year term).
- Philippe Calais appointed CEO; Thomas Fitzgerald remains CFO; Elizabeth Czerepak joins board and chairs Audit Committee.
- Filed Certificate of Designation for Series A and B non-voting convertible preferred stock with PIK dividends and conversion rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925097799/0001104659-25-097799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925097799/tm2528282d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer